Clinical Trials
24 trialsTrimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer
Canadian Cancer Trials Group
Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)
SWOG Cancer Research Network
Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer
Radiation Therapy Oncology Group
COXEN
SWOG Cancer Research Network
Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract
Eastern Cooperative Oncology Group
Chemotherapy in Treating Patients With Early-Stage Bladder Cancer
Eastern Cooperative Oncology Group
Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function
Eastern Cooperative Oncology Group
Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium
Eastern Cooperative Oncology Group
Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer
Eastern Cooperative Oncology Group
Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery
Radiation Therapy Oncology Group
Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer
Radiation Therapy Oncology Group
S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract
SWOG Cancer Research Network
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
SWOG Cancer Research Network
S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium
SWOG Cancer Research Network
S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium
SWOG Cancer Research Network
S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy
SWOG Cancer Research Network
S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium
SWOG Cancer Research Network
S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract
SWOG Cancer Research Network
Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract
European Organisation for Research and Treatment of Cancer - EORTC
SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract
European Organisation for Research and Treatment of Cancer - EORTC
BCG With or Without Mitomycin in Treating Patients With Bladder Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Transurethral Resection and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Radiation Therapy and Chemotherapy Following Surgery in Treating Patients With Stage II or Stage III Bladder Cancer
European Organisation for Research and Treatment of Cancer - EORTC